Recently, it was reported that human neutrophil elastase was able to cleave biological drugs used in IBD patients (infliximab, adalimumab, etanercept, and vedolizumab), impairing the TNFα‐neutralizing capacity of such therapeutic agents (Curciarello et al., 2020). Here, ELANE is linked to inflammatory bowel disease.